Erasca, Inc.
Moat Score — Erasca, Inc.
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Erasca's IP position is still largely pending (only 1 issued U.S. patent as of year-end 2025, versus dozens of pending U.S., PCT, and foreign applications), so intangible protection exists in potential but is not yet secured; scientific know-how and in-licensed compounds from Joyo and Medshine add some proprietary value. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-revenue clinical-stage biotech with no manufacturing or commercial scale, Erasca has no demonstrated cost advantage versus peers or larger pharmaceutical competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved or marketed products, Erasca has no pricing power today; any future pricing power is entirely speculative and contingent on clinical and regulatory success. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | No network effects are present or applicable to a clinical-stage drug developer with no platform, user base, or marketplace dynamics. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | There are no customers or prescribers currently using Erasca products, so no switching costs exist; this could change only after an approved, adopted therapy, which is not yet the case. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The FDA approval process and the scientific/capital barriers to RAS/MAPK drug discovery provide some structural protection against new entrants, but Erasca itself has not achieved efficient scale and remains dependent on continued external financing and licensing income. |